Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series
- 774 Downloads
A single institution retrospective evaluation of nivolumab following disease progression on bevacizumab in adults with recurrent glioblastoma (GBM) with an objective of determining progression free survival (PFS). There is no accepted therapy for recurrent GBM after failure of bevacizumab. 16 adults, ages 52–72 years (median 62), with recurrent GBM were treated. All patients had previously been treated with surgery, concurrent radiotherapy and temozolomide, and post-radiotherapy temozolomide. Bevacizumab (with or without lomustine) was administered to all patients at first recurrence. Patients were treated with nivolumab only (3 mg/kg) once every 2 weeks at second recurrence. One cycle of nivolumab was defined as 2 treatments. Neurological evaluation was performed bi-weekly and neuroradiographic assessment every 4 weeks. A total of 37 treatment cycles (median 2) were administered of nivolumab in which there were 14 Grade 2 adverse events (AEs) and Grade 3 AEs in two patients. No Grade 4 or 5 AEs were seen. Following 1 month of nivolumab, seven patients demonstrated progressive disease and discontinued therapy. No patient demonstrated a response though nine patients demonstrated neuroradiographic stable response. Survival in the entire cohort ranged from 2 to 6 months with a median of 3.5 months (CI 2.8, 4.2). Median and 6-month PFS at 6 months was 2.0 months (range 1–5 months; CI 1.3, 2.7) and 0% respectively. Nivolumab salvage therapy demonstrated no survival advantage in patients with recurrent bevacizumab refractory GBM emphasizing a continued unmet need in neuro-oncology.
KeywordsNivolumab Immune checkpoint inhibitor Recurrent glioblastoma Bevacizumab refractory
MC Chamberlain collected and analyzed data.
Compliance with ethical standards
Conflict of interest
The author reports no conflict of interest.
- 1.de Groot JF (2015) High-grade gliomas. Continuum (Minneap Minn). Neuro-oncology 21(2):332–344Google Scholar
- 27.Wick W, Stupp R, Gorlia T et al (2016) EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. J Clin Oncol 33(15s) (Abstract 2001)Google Scholar
- 30.Hovey EJ, Field KM, Rosenthal M et al (2015) Continuing or ceasing bevacizumab at disease progression: results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma. J Clin Oncol 33(15s) (suppl; abstr 2003)Google Scholar
- 33.Ahluwalia MS, Rogers LR, Chaudhary RT et al (2016) A phase 2 trial of TRC105 with bevacizumab for bevacizumab refractory glioblastoma. J Clin Oncol 33(15s) (abstract 2035)Google Scholar
- 43.Brenner AJ, Cohen YC, Vredenburgh JJ et al (2016) Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: a phase 2 historically controlled trial. J Clin Oncol 33(15s) (abstract 2074)Google Scholar
- 44.Bota DA, Desjardins A, Mason WP et al (2016) Phase 1, multicenter, open-label, dose escalation, study of marizomib (MRZ) and bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG). J Clin Oncol 34(18s) (abstract 2037)Google Scholar
- 45.Goldlust SA, Nabors LB, Mohile N et al (2016) Phase 1/2 trial of bevacizumab plus TPI 287, a brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma. J Clin Oncol 34(18s) (abstract 2055)Google Scholar
- 46.Nayak L, Hays JL, Muzikansky A et al (2016) A phase I study of MLN0128 and bevacizumab in patients with recurrent glioblastoma and other solid tumors. J Clin Oncol 33(15s) (abstract 2013)Google Scholar
- 47.Hoang-Xuan K, Hottinger A, Royer-Perron L et al (2016) Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma. J Clin Oncol 33(15s) (abstract 2033)Google Scholar
- 48.Reardon DA, De Groot JF, Colman H et al (2016) Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM). J Clin Oncol 33(15s) (abstract 2010)Google Scholar